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I
n the United States, selective 
serotonin reuptake inhibitor (SSRI) 
antidepressants are advertised 
directly to consumers [1]. These 
highly successful direct-to-consumer 
advertising (DTCA) campaigns have 
largely revolved around the claim that 
SSRIs correct a chemical imbalance 
caused by a lack of serotonin (see 
Tables 1 and 2). For instance, sertraline 
(Zoloft) was the sixth best-selling 
medication in the US in 2004, with 
over $3 billion in sales [2] likely due, at 
least in part, to the widely disseminated 
advertising campaign starring Zoloft’s 
miserably depressed ovoid creature. 
Research has demonstrated that class-
wide SSRI advertising has expanded 
the size of the antidepressant market 
[3], and SSRIs are now among the best-
selling drugs in medical practice [2].
Given the multifactorial nature 
of depression and anxiety, and the 
ambiguities inherent in psychiatric 
diagnosis and treatment, some have 
questioned whether the mass provision 
of SSRIs is the result of an over-
medicalized society. These sentiments 
were voiced by Lord Warner, United 
Kingdom Health Minister, at a recent 
hearing: “…I have some concerns 
that sometimes we do, as a society, 
wish to put labels on things which 
are just part and parcel of the human 
condition”[4]. He went on to say, 
“Particularly in the area of depression 
we did ask the National Institute for 
Clinical Excellence [an independent 
health organisation that provides 
national guidance on treatment and 
prevention] to look into this particular 
area and their guideline on depression 
did advise non-pharmacological 
treatment for mild depression” [4]. 
Sentiments such as Lord Warner’s, 
about over-medicalization, are exactly 
what some pharmaceutical companies 
have sought to overcome with their 
advertising campaigns. For example, 
Pﬁ  zer’s television advertisement for 
the antidepressant sertraline (Zoloft) 
stated that depression is a serious 
medical condition that may be due to 
a chemical imbalance, and that “Zoloft 
works to correct this imbalance” [5]. 
Other SSRI advertising campaigns 
have also claimed that depression 
is linked with an imbalance of the 
neurotransmitter serotonin, and that 
SSRIs can correct this imbalance (see 
Table 2). The pertinent question is: are 
the claims made in SSRI advertising 
congruent with the scientiﬁ  c evidence?
The Serotonin Hypothesis 
In 1965, Joseph Schildkraut put 
forth the hypothesis that depression 
was associated with low levels of 
norepinephrine [6], and later 
researchers theorized that serotonin 
was the neurotransmitter of interest 
[7]. In subsequent years, there 
were numerous attempts to identify 
reproducible neurochemical 
alterations in the nervous systems of 
patients diagnosed with depression. 
For instance, researchers compared 
levels of serotonin metabolites in 
the cerebrospinal ﬂ  uid of clinically 
depressed suicidal patients to controls, 
but the primary literature is mixed and 
plagued with methodological difﬁ  culties 
such as very small sample sizes and 
uncontrolled confounding variables. 
In a recent review of these studies, 
the chairman of the German Medical 
Board and colleagues stated, “Reported 
associations of subgroups of suicidal 
behavior (e.g. violent suicide attempts) 
with low CSF–5HIAA [serotonin] 
concentrations are likely to represent 
somewhat premature translations of 
ﬁ  ndings from studies that have ﬂ  aws 
in methodology” [8]. Attempts were 
also made to induce depression by 
depleting serotonin levels, but these 
experiments reaped no consistent 
results [9]. Likewise, researchers found 
that huge increases in brain serotonin, 
arrived at by administering high-dose L-
tryptophan, were ineffective at relieving 
depression [10].
The Essay section contains opinion pieces on topics 
of broad interest to a general medical audience. 
Serotonin and Depression: A Disconnect 
between the Advertisements 
and the Scientiﬁ  c Literature
Jeffrey R. Lacasse, Jonathan Leo*
Citation: Lacasse JR, Leo J (2005) Serotonin 
and depression: A disconnect between the 
advertisements and the scientiﬁ  c literature. PLoS Med 
2(12): e392.
Copyright: © 2005 Lacasse and Leo. This is an open-
access article distributed under the terms of the 
Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in 
any medium, provided the original author and source 
are credited.
Abbreviations: DTCA, direct-to-consumer 
advertising; FDA, Food and Drug Administration; SSRI, 
selective serotonin reuptake inhibitor
Jeffrey R. Lacasse is at Florida State University College 
of Social Work, Tallahassee, Florida, United States 
of America. Jonathan Leo is at Lake Erie College of 
Osteopathic Medicine, Bradenton, Florida, United 
States of America.
Competing Interests: The authors declare that no 
competing interests exist and that they received no 
funding for this work.




(Illustration: Margaret Shear, Public Library of 
Science)PLoS Medicine  |  www.plosmedicine.org 1212
Contemporary neuroscience research 
has failed to conﬁ  rm any serotonergic 
lesion in any mental disorder, and 
has in fact provided signiﬁ  cant 
counterevidence to the explanation of 
a simple neurotransmitter deﬁ  ciency. 
Modern neuroscience has instead 
shown that the brain is vastly complex 
and poorly understood [11]. While 
neuroscience is a rapidly advancing 
ﬁ  eld, to propose that researchers 
can objectively identify a “chemical 
imbalance” at the molecular level 
is not compatible with the extant 
science. In fact, there is no scientiﬁ  cally 
established ideal “chemical balance” 
of serotonin, let alone an identiﬁ  able 
pathological imbalance. To equate 
the impressive recent achievements 
of neuroscience with support for the 
serotonin hypothesis is a mistake. 
With direct proof of serotonin 
deﬁ  ciency in any mental disorder 
lacking, the claimed efﬁ  cacy of SSRIs 
is often cited as indirect support 
for the serotonin hypothesis. Yet, 
this ex juvantibus line of reasoning 
(i.e., reasoning “backwards” to make 
assumptions about disease causation 
based on the response of the disease to 
a treatment) is logically problematic—the 
fact that aspirin cures headaches does 
not prove that headaches are due 
to low levels of aspirin in the brain. 
Serotonin researchers from the US 
National Institute of Mental Health 
Laboratory of Clinical Science clearly 
state, “[T]he demonstrated efﬁ  cacy of 
selective serotonin reuptake inhibitors…
cannot be used as primary evidence 
for serotonergic dysfunction in the 
pathophysiology of these disorders” [12].
Reasoning backwards, from SSRI 
efﬁ  cacy to presumed serotonin 
deﬁ  ciency, is thus highly contested. 
The validity of this reasoning becomes 
even more unlikely when one 
considers recent studies that even call 
into question the very efﬁ  cacy of the 
SSRIs. Irving Kirsch and colleagues, 
using the Freedom of Information 
Act, gained access to all clinical trials 
of antidepressants submitted to the 
Food and Drug Administration (FDA) 
by the pharmaceutical companies 
for medication approval. When the 
published and unpublished trials were 
pooled, the placebo duplicated about 
80% of the antidepressant response 
[13]; 57% of these pharmaceutical 
company–funded trials failed to show 
a statistically signiﬁ  cant difference 
between antidepressant and inert 
placebo [14]. A recent Cochrane 
review suggests that these results are 
inﬂ  ated as compared to trials that use 
an active placebo [15]. This modest 
efﬁ  cacy and extremely high rate of 
placebo response are not seen in the 
treatment of well-studied imbalances 
such as insulin deﬁ  ciency, and casts 
doubt on the serotonin hypothesis.
Also problematic for the serotonin 
hypothesis is the growing body 
of research comparing SSRIs to 
interventions that do not target 
serotonin speciﬁ  cally. For instance, a 
Cochrane systematic review found no 
major difference in efﬁ  cacy between 
SSRIs and tricyclic antidepressants [16]. 
In addition, in randomized controlled 
trials, buproprion [17] and reboxetine 
[18] were just as effective as the 
SSRIs in the treatment of depression, 
yet neither affects serotonin to any 
signiﬁ  cant degree. St. John’s Wort [19] 
and placebo [20] have outperformed 
SSRIs in recent randomized controlled 
trials. Exercise was found to be as 
effective as the SSRI sertraline in a 
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Table 1. Selected Quotations Regarding Serotonin and Antidepressants
Quotation Source
“Although it is often stated with great conﬁ  dence that depressed people have a 
serotonin or norepinephrine deﬁ  ciency, the evidence actually contradicts these 
claims” [50].
Professor Emeritus of Neuroscience Elliot Valenstein, in Blaming the Brain (1998), which 
reviews the evidence for the serotonin hypothesis.
“Given the ubiquity of a neurotransmitter such as serotonin and the multiplicity 
of its functions, it is almost as meaningless to implicate it in depression as it is to 
implicate blood” [11]. 
Science writer John Horgan, in his critical examination of modern neuroscience, The
Undiscovered Mind (1999).
“A serotonin deﬁ  ciency for depression has not been found” [51]. Psychiatrist Joseph Glenmullen, clinical instructor of psychiatry at Harvard Medical
School, in Prozac Backlash (2000).
“So far, there is no clear and convincing evidence that monoamine deﬁ  ciency 
accounts for depression; that is, there is no “real” monoamine deﬁ  cit” [44].
Psychiatrist Stephen M. Stahl, in a textbook used to teach medical students about 
psychiatric medications, Essential Psychopharmacology (2000).
“Some have argued that depression may be due to a deﬁ  ciency of NE 
[norepinephrine] or 5-HT [serotonin] because the enhancement of noradrenergic 
or serotonergic neurotransmission improves the symptoms of depression. However, 
this is akin to saying that because a rash on one’s arm improves with the use of a 
steroid cream, the rash must be due to a steroid deﬁ  ciency” [52]. 
Psychiatrists Pedro Delgado and Francisco Moreno, in “Role of Norepinephrine in 
Depression,” published in the Journal of Clinical Psychiatry in 2000. 
“…I wrote that Prozac was no more, and perhaps less, effective in treating major 
depression than prior medications…. I argued that the theories of brain functioning 
that led to the development of Prozac must be wrong or incomplete” [53].
Brown University psychiatrist Peter Kramer, author of Listening to Prozac, which is often 
credited with popularizing SSRIs, in a clarifying letter to the New York Times in 2002.
“I spent the ﬁ  rst several years of my career doing full-time research on brain 
serotonin metabolism, but I never saw any convincing evidence that any psychiatric 
disorder, including depression, results from a deﬁ  ciency of brain serotonin. In fact, 
we cannot measure brain serotonin levels in living human beings so there is no way 
to test this theory. Some neuroscientists would question whether the theory is even 
viable, since the brain does not function in this way, as a hydraulic system” [54].
Stanford psychiatrist David Burns, winner of the A.E. Bennett Award given by the 
Society for Biological Psychiatry for his research on serotonin metabolism, when asked 
about the scientiﬁ  c status of the serotonin theory in 2003.
“Indeed, no abnormality of serotonin in depression has ever been demonstrated” 
[55].
Psychiatrist David Healy, former secretary of the British Association for 
Psychopharmacology and historian of the SSRIs, in Let Them Eat Prozac (2004).
“We have hunted for big simple neurochemical explanations for psychiatric 
disorders and have not found them” [56].
Psychiatrist Kenneth Kendler the coeditor-in-chief of Psychological Medicine, in a 2005 
review article.
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randomized controlled trial [21]. The 
research and development activities 
of pharmaceutical companies also 
illustrate a diminishing role for 
serotonergic intervention—Eli Lilly, 
the company that produced ﬂ  uoxetine 
(Prozac), recently released duloxetine, 
an antidepressant designed to impact 
norepinephrine as well as serotonin. 
The evidence presented above thus 
seems incompatible with a speciﬁ  c 
serotonergic lesion in depression. 
Although SSRIs are considered 
“antidepressants,” they are FDA-
approved treatments for eight separate 
psychiatric diagnoses, ranging from 
social anxiety disorder to obsessive-
compulsive disorder to premenstrual 
dysphoric disorder. Some consumer 
advertisements (such as the Zoloft and 
Paxil Web sites) promote the serotonin 
hypothesis, not just for depression, but 
also for some of these other diagnostic 
categories [22,23]. Thus, for the 
serotonin hypothesis to be correct 
as currently presented, serotonin 
regulation would need to be the 
cause (and remedy) of each of these 
disorders [24]. This is improbable, 
and no one has yet proposed a cogent 
theory explaining how a singular 
putative neurochemical abnormality 
could result in so many wildly differing 
behavioral manifestations.
In short, there exists no rigorous 
corroboration of the serotonin theory, 
and a signiﬁ  cant body of contradictory 
evidence. Far from being a radical line 
of thought, doubts about the serotonin 
hypothesis are well acknowledged 
by many researchers, including 
frank statements from prominent 
psychiatrists, some of whom are even 
enthusiastic proponents of SSRI 
medications (see Table 1). 
However, in addition to what these 
authors say about serotonin, it is 
also important to look at what is not 
said in the scientiﬁ  c literature. To 
our knowledge, there is not a single 
peer-reviewed article that can be 
accurately cited to directly support 
claims of serotonin deﬁ  ciency in any 
mental disorder, while there are many 
articles that present counterevidence. 
Furthermore, the Diagnostic and 
Statistical Manual of Mental Disorders 
(DSM), which is published by the 
American Psychiatric Association 
and contains the deﬁ  nitions of all 
psychiatric diagnoses, does not list 
serotonin as a cause of any mental 
disorder. The American Psychiatric Press 
Textbook of Clinical Psychiatry addresses 
serotonin deﬁ  ciency as an unconﬁ  rmed 
hypothesis, stating, “Additional 
experience has not conﬁ  rmed the 
monoamine depletion hypothesis” [25].
Consumer Advertisements of 
Antidepressants
Contrary to what many people believe, 
the FDA does not require preapproval 
of advertisements. Instead, the FDA 
monitors the advertisements once 
they are in print or on the air [26]. 
Misleading content is frequently 
found in various DTCA campaigns 
[27]; hence, it is valuable to compare 
SSRI advertisements to the scientiﬁ  c 
evidence reviewed above. These SSRI 
ads are widely promulgated; hundreds 
of millions of dollars have been spent 
disseminating these advertisements, 
and one study found that over 70% of 
surveyed patients reported exposure to 
antidepressant DTCA [28].
The Role of the FDA 
In the US, the FDA monitors and 
regulates DTCA. The FDA requires 
that advertisements “cannot be false 
or misleading” and “must present 
information that is not inconsistent 
with the product label” [27]. 
Pharmaceutical companies that 
disseminate advertising incompatible 
with these requirements can receive 
warning letters and can be sanctioned. 
The Irish equivalent of the FDA, the 
Irish Medical Board, recently banned 
GlaxoSmithKline from claiming 
that paroxetine corrects a chemical 
imbalance even in their patient 
information leaﬂ  ets [29]. Should 
the FDA take similar action against 
consumer advertisements of SSRIs? 
As just one example, the prescribing 
information for paroxetine, which 
is typical of the SSRI-class drugs, 
states, “The efﬁ  cacy of paroxetine in 
December 2005  |  Volume 2  |  Issue 12  |  e392
Table 2. Selected Consumer Advertisements from SSRIs from Print, Television, and the World Wide Web
Medication Selected Content from Consumer Advertisement 
Citalopram “Celexa helps to restore the brain’s chemical balance by increasing the supply of a chemical messenger in the brain called serotonin. Although 
the brain chemistry of depression is not fully understood, there does exist a growing body of evidence to support the view that people with 
depression have an imbalance of the brain’s neurotransmitters” [57].
Escitalopram  “LEXAPRO appears to work by increasing the available supply of serotonin. Here’s how:
The naturally occurring chemical serotonin is sent from one nerve cell to the next.
The nerve cell picks up the serotonin and sends some of it back to the ﬁ  rst nerve cell, similar to a conversation between two people.
In people with depression and anxiety, there is an imbalance of serotonin—too much serotonin is reabsorbed by the ﬁ  rst nerve cell, so the 
next cell does not have enough; as in a conversation, one person might do all the talking and the other person does not get to comment, 
leading to a communication imbalance.
LEXAPRO blocks the serotonin from going back into the ﬁ  rst nerve cell. This increases the amount of serotonin available for the next nerve 
cell, like a conversation moderator.
The blocking action helps balance the supply of serotonin, and communication returns to normal. In this way, LEXAPRO improves symptoms 
of depression” [58].
Fluoxetine “When you’re clinically depressed, one thing that can happen is the level of serotonin (a chemical in your body) may drop. So you may 
have trouble sleeping. Feel unusually sad or irritable. Find it hard to concentrate. Lose your appetite. Lack energy. Or have trouble feeling 
pleasure…to help bring serotonin levels closer to normal, the medicine doctors now prescribe most often is Prozac®” [59].
Paroxetine “Chronic anxiety can be overwhelming. But it can also be overcome…Paxil, the most prescribed medication of its kind for generalized anxiety, 
works to correct the chemical imbalance believed to cause the disorder” [60]. 
Sertraline “While the cause is unknown, depression may be related to an imbalance of natural chemicals between nerve cells in the brain. Prescription 
Zoloft works to correct this imbalance. You just shouldn’t have to feel this way anymore” [5].
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the treatment of major depressive 
disorder, social anxiety disorder, 
obsessive-compulsive disorder (OCD), 
panic disorder (PD), generalized 
anxiety disorder (GAD), and post-
traumatic stress disorder (PTSD) is 
presumed to be linked to potentiation 
of serotonergic activity in the central 
nervous system resulting from 
inhibition of neuronal reuptake of 
serotonin. Studies at clinically relevant 
doses in humans have demonstrated 
that paroxetine blocks the uptake of 
serotonin into human platelets” [30].
In other words, the mechanism of 
action of paroxetine has not been 
deﬁ  nitively established, and remains 
unconﬁ  rmed and presumptive (the 
prescribing information states that 
the efﬁ  cacy of the drug “is presumed 
to be linked to potentiation of 
serotonergic activity” ([30], our italics 
added). Although there is evidence 
that paroxetine inhibits the reuptake 
of serotonin, the signiﬁ  cance of this 
phenomenon in the amelioration of 
psychiatric symptoms is unknown, 
and continually debated [12,31]. 
Most importantly, the prescribing 
information does not mention 
a serotonin deﬁ  ciency in those 
administered paroxetine, nor does 
it claim that paroxetine corrects an 
imbalance of serotonin. In contrast, the 
consumer advertisements for paroxetine 
present claims that are not found in this 
FDA-approved product labeling.
In order to determine whether these 
advertisements actually comply with 
FDA regulations, it is useful to consult 
the Code of Federal Regulations 
under which DTCA is regulated. The 
regulations state that an advertisement 
may be cited as false or misleading 
if it “[c]ontains claims concerning 
the mechanism or site of drug action 
that are not generally regarded as 
established by scientiﬁ  c evidence by 
experts qualiﬁ  ed by scientiﬁ  c training 
and experience without disclosing 
that the claims are not established 
and the limitations of the supporting 
evidence…” ([32], our emphasis 
added]).
Stating that depression may be 
due to a serotonin deﬁ  ciency is 
seemingly allowed, but, as stated in 
the regulations, only if the limitations 
of the supporting evidence are 
provided. In our examination of SSRI 
advertisements, we did not locate a 
single advertisement that presented 
any such information. Instead, the 
serotonin hypothesis is typically 
presented as a collective scientiﬁ  c 
belief, as in the Zoloft advertisement, 
which states that regarding depression, 
“Scientists believe that it could be 
linked with an imbalance of a chemical 
in the brain called serotonin” [33]. 
Consumers viewing such advertisements 
remain uninformed regarding the 
limitations of the serotonin hypothesis 
(reviewed above).
According to federal regulations, 
advertisements are also proscribed 
from including content that “contains 
favorable information or opinions 
about a drug previously regarded as 
valid but which have been rendered 
invalid by contrary and more credible 
recent information” [32].
This means that a disconnect 
between the evolving peer-reviewed 
literature and advertisements is 
not permitted. Regarding SSRIs, 
there is a growing body of medical 
literature casting doubt on the 
serotonin hypothesis, and this body 
is not reﬂ  ected in the consumer 
advertisements. In particular, many 
SSRI advertisements continue to 
claim that the mechanism of action of 
SSRIs is that of correcting a chemical 
imbalance, such as a paroxetine 
advertisement, which states, “With 
continued treatment, Paxil can help 
restore the balance of serotonin…” 
[22]. Yet, as previously mentioned, 
there is no such thing as a scientiﬁ  cally 
established correct “balance” of 
serotonin. The take-home message for 
consumers viewing SSRI advertisements 
is probably that SSRIs work by 
normalizing neurotransmitters that 
have gone awry. This was a hopeful 
notion 30 years ago, but is not an 
accurate reﬂ  ection of present-day 
scientiﬁ  c evidence. 
The FDA has sent ten warning letters 
to antidepressant manufacturers since 
1997 [34–43], but has never cited 
a pharmaceutical company for the 
issues covered here. The reasons for 
their inaction are unclear but seem 
to result from a deliberate decision at 
some level of the FDA, rather than an 
oversight. Since 2002, the ﬁ  rst author 
(JRL) has repeatedly contacted the 
FDA regarding these issues. The only 
substantive response was an E-mail 
received from a regulatory reviewer 
at the FDA: “Your concern regarding 
direct-to-consumer advertising raises an 
interesting issue regarding the validity 
of reductionistic statements. These 
statements are used in an attempt to 
describe the putative mechanisms 
of neurotransmitter action(s) to the 
fraction of the public that functions 
at no higher than a 6th grade reading 
level” (personal communication, 2002 
April 11).
It is curious that these advertisements 
are rationalized as being appropriate 
for those with poor reading skills. If 
the issues surrounding antidepressants 
are too complex to explain accurately 
to the general public, one wonders 
why it is imperative that DTCA of 
antidepressants be permitted at all. 
However, contrary to what the FDA 
seems to be implying, truth and 
simplicity are not mutually exclusive. 
Consider the medical textbook, 
Essential Psychopharmacology, which 
states, “So far, there is no clear and 
convincing evidence that monoamine 
deﬁ  ciency accounts for depression; that 
is, there is no ‘real’ monoamine deﬁ  cit” 
[44]. Like the pharmaceutical company 
advertisements, this explanation is very 
easy to understand, yet it paints a very 
different picture about the serotonin 
hypothesis. 
Conclusion
The impact of the widespread 
promotion of the serotonin hypothesis 
should not be underestimated. 
Antidepressant advertisements are 
ubiquitous in American media, and 
there is emerging evidence that these 
advertisements have the potential 
to confound the doctor–patient 
relationship. A recent study by Kravitz 
et al. found that pseudopatients 
(actors who were trained to behave as 
patients) presenting with symptoms of 
adjustment disorder (a condition for 
which antidepressants are not usually 
prescribed) were frequently prescribed 
paroxetine (Paxil) by their physicians 
if they inquired speciﬁ  cally about 
Paxil [45]; such enquiries from actual 
patients could be prompted by DTCA 
[45].
What remains unmeasured, though, 
is how many patients seek help from 
their doctor because antidepressant 
advertisements have convinced them 
that they are suffering from a serotonin 
deﬁ  ciency. These advertisements 
present a seductive concept, and the 
fact that patients are now presenting 
with a self-described “chemical 
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imbalance” [46] shows that the DTCA 
is having its intended effect: the 
medical marketplace is being shaped 
in a way that is advantageous to the 
pharmaceutical companies. Recently, 
it has been alleged that the FDA is 
more responsive to the concerns of 
the pharmaceutical industry than 
to their mission of protecting US 
consumers, and that enforcement 
efforts are being relaxed [47]. Patients 
who are convinced they are suffering 
from a neurotransmitter defect are 
likely to request a prescription for 
antidepressants, and may be skeptical 
of physicians who suggest other 
interventions, such as cognitive-
behavioral therapy [48], evidence-
based or not. Like other vulnerable 
populations, anxious and depressed 
patients “are probably more susceptible 
to the controlling inﬂ  uence of 
advertisements” [49].
In 1998, at the dawn of consumer 
advertising of SSRIs, Professor Emeritus 
of Neuroscience Elliot Valenstein 
summarized the scientiﬁ  c data by 
concluding, “What physicians and the 
public are reading about mental illness 
is by no means a neutral reﬂ  ection of 
all the information that is available” 
[50]. The current state of affairs 
has only conﬁ  rmed the veracity of 
this conclusion. The incongruence 
between the scientiﬁ  c literature and 
the claims made in FDA-regulated 
SSRI advertisements is remarkable, and 
possibly unparalleled.  
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